AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members.
Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
AHA urges the Centers for Medicare & Medicaid Services (CMS) to withdraw the condition of participation that hospitals report daily COVID-19 data.
Letter from AHA to President Donald Trump urging additional support for rural hospitals and health systems.
On behalf of the nation’s 340B hospitals, AHA, others urge HHS to protect vulnerable communities from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and other health care services.
AHA urges the Centers for Medicare & Medicaid Services to provide additional flexibility regarding the agency’s new COVID-19 test documentation requirement for the diagnostic-related group (DRG) add-on payment.
AHA comments on the Centers for Medicare & Medicaid Services’ calendar year 2021 proposed rule for the Home Health prospective payment system (PPS).
AHA to Eli Lilly and Company Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Sanofi U.S./Sanofi Genzyme are taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions AztraZeneca is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.
AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.